Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using ¹⁷⁷Lu-iPSMA and ¹⁷⁷Lu-DOTATOC: Experience after 905 Treatment Doses

• Main Authors: Myrna Luna-Gutiérrez (Author), Rodrigo Hernández-Ramírez (Author), Airam Soto-Abundiz (Author), Osvaldo García-Pérez (Author), Alejandra Ancira-Cortez (Author), Sergio López-Buenrostro (Author), Brenda Gibbens-Bandala (Author), Irma Soldevilla-Gallardo (Author), Nancy Lara-Almazán (Author), Melissa Rojas-Pérez (Author), Blanca Ocampo-García (Author), Erika Azorín-Vega (Author), Clara Santos-Cuevas (Author), Guillermina Ferro-Flores (Author)
• Format: Book
• Published: MDPI AG, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

¹⁷⁷Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC). ¹⁷⁷Lu-DOTATOC is a pate...